Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMART: Medical Treatment vs Surgery in Stricturing Crohn's Disease
NCT05584228Not yet recruiting
- Sponsor
- CHU de Nantes
- Start
- Oct 2026
- Primary completion
- Apr 2030
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised, open-label trial of infliximab and azathioprine in Crohn's disease (2 arms), sponsored by CHU de Nantes. Primary endpoint: Inflammatory Bowel Disease-related Quality of Life at 12 months. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
infliximabazathioprine
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT05584228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05584228.